0.00060.00% ( 0.0000 )
Delay Closed: Oct 27, 16:00:00 (EDT)Current ValuationThe current P/E ratio is -0.08, within the reasonable range, cheaper than 84.4% of the time in the past 3 years, and the industry ranks 62/173, the industry Median -0.80.
-0.0755xP/E
$0.00Stock price
$-0.01Earnings per share
-0.0755xP/E
Stock price$0.00Earnings per share$-0.01
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.08x
- Typical range
- -0.08x–-0.08x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
014284256
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
| Name/Symbol | |||
|---|---|---|---|
BAXUSBaxter | -12.30x | 140.96% | $13.07B |
GKOSUSGlaukos | -55.92x | 75.37% | $10.52B |
TFXUSTeleflex | -5.62x | 118.39% | $5.80B |
IRTCUSIRhythm | -288.18x | 71.47% | $4.02B |
PLSEUSPulse Biosciences | -46.92x | 26.85% | $3.76B |
ASSTUSStrive | -3.35x | 57.99% | $3.27B |
AXGNUSAxogen | -66.49x | 16.18% | $2.23B |
BFLYUSButterfly Network | -23.69x | 31.45% | $1.77B |
KMTSUSKestra Medical Tech | -11.50x | 0.79% | $1.72B |
ATECUSAlphatec | -15.31x | 41.67% | $1.68B |
NVCRUSNovocure | -11.29x | 1.23% | $1.68B |
TNDMUSTandem Diabetes | -20.77x | 77.60% | $1.32B |
ENOVUSEnovis | -1.11x | 100.97% | $1.22B |
DRTSUSAlpha Tau Medical | -12.86x | -- | $1.19B |
PRCTUSPROCEPT BioRobotics | -10.35x | 3.47% | $1.14B |
AORTUSArtivion | -351.12x | 266.67% | $1.12B |
BBNXUSBeta Bionics | -14.80x | 11.45% | $1.08B |
CBLLUSCeribell | -15.72x | 35.15% | $1.04B |
SIBNUSSI-BONE | -65.27x | 8.85% | $955.08M |
QDELUSQuidelOrtho | -0.90x | 75.33% | $944.28M |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
